Roche Faces New Foe as Boehringer Plans a Rituxan Copy Bloomberg Rituxan, also know by its generic name rituximab, had 6 billion Swiss francs ($6.45 billion) in sales last year. Roche's patents on the medicine expire in 2018 in the U.S. and earlier in Europe. Biogen Idec Inc. (BIIB) helps market the drug in the U.S ... |
